Zura Bio Clinical Trial Data
Zura Bio announced that its Phase 2 TibuSHIELD study of tibulizumab (ZB-106) in adults with moderate-to-severe hidradenitis suppurativa (HS) failed to meet its primary endpoint of percentage change from baseline in total abscess and inflammatory nodule count at Week 16. Key secondary endpoints were also not met, leading the company to discontinue development of the drug for the HS indication. Zura will continue its ongoing trials for tibulizumab in systemic sclerosis and polymyalgia rheumatica.